Exclusive special offer and discount title banner vector image

GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET FORECAST 2023-2032

SCOPE OF THE REPORT

Global Head & Neck Cancer Therapeutics Market by Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors) Market by Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery) Market by Route of Administration (Injectable, Oral) Market by End-user (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-users) by Geography


MARKET OVERVIEW

The global head & neck cancer therapeutics market is expected to reach $3041.91 million by 2032, growing at a CAGR of 8.60% during the forecast period, 2023-2032

Head and neck cancer refers to a collection of cancerous tumors that appear in the tissues of the head and neck area. The oral cavity (mouth), throat (pharynx), voice box (larynx), salivary glands, nasal cavity, and sinuses are among the various locations that fall under this category. Numerous factors, such as the use of tobacco, excessive alcohol consumption, exposure to certain chemicals and substances, infection with specific types of human papillomavirus, poor oral hygiene, and certain genetic factors, can contribute to the development of head and neck cancer.

Personalized treatment plans have also been made possible by developments in precision medicine methods like biomarker identification. Due to their promise to lower morbidity and enhance functional outcomes, minimally invasive surgical techniques, such as transoral robotic surgery and endoscopic procedures, have grown in popularity. Moreover, the development of innovative treatments is accelerating as a result of collaborative research initiatives involving pharmaceutical corporations, academic institutions, and research groups.

Head & Neck Cancer Therapeutics Market

Read our latest blog on the Head & Neck Cancer Therapeutics Market

GROWTH ENABLERS

KEY GROWTH ENABLERS OF THE GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET ARE:

  • Increasing incidence of head and neck cancers
    • In 2022, the American Society of Clinical Oncology stated that head and neck cancer is the seventh most common disease worldwide, with about 1 million cases identified each year. Subsequently, the high incidence of head and neck cancer cases is expected to promote opportunities for research and clinical trials.
    • Tobacco use and excessive alcohol use are two major risk factors for developing head and neck cancer. According to the Centers for Disease Control and Prevention (CDC), around 4 out of every 100 middle school children (4.5%) and approximately 1 out of every 6 high school students (16.5%) reported current use of a tobacco product in 2022. However, despite improved public awareness and efforts to minimize tobacco as well as alcohol use, these behaviors persist and contribute to the illness burden.
    • There has been an upsurge in oropharyngeal cancers associated with high-risk strains of HPV, particularly HPV16, in recent years. According to the Centers for Disease Control and Prevention (CDC), around 47,199 new instances of cancer are discovered each year in areas of the body where human papillomavirus (HPV) is commonly prevalent. HPV-related oropharyngeal malignancies primarily affect younger people who may not have a history of established risk factors like smoking or excessive alcohol intake. Several countries, notably the United States, have also seen an increase in HPV-related cases.
  • Advancements in treatment modalities
  • Advances in biochemistry and genomics
  • Increasing geriatric population

GROWTH RESTRAINTS

KEY GROWTH RESTRAINING FACTORS OF THE GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET ARE:

  • Severe side effects
    • Certain cancer treatments, such as radiation therapy and chemotherapy medications, may have long-term consequences, like an increased risk of subsequent malignancies or organ and tissue damage. Besides, follow-up treatment is required on a regular basis to detect and manage any potential long-term complications.
    • Chemotherapy and several targeted medicines can depress the immune system, making individuals more vulnerable to infections. Hence, it is critical to take precautions such as avoiding contact with patients and exercising excellent hygiene.
    • Chemotherapy and radiation therapy can also reduce blood cell synthesis, resulting in anemia, neutropenia, and thrombocytopenia. This increases the likelihood of infection, tiredness, and bleeding. Hence, the associated side effects of chemotherapy treatment have implications on the demand for head & neck cancer therapeutics, thus hindering market growth.
  • High treatment costs
  • Limited effective treatment options for head & neck cancer

To Know More About This Report, Request a Free Sample Copy

KEY MARKET TRENDS

Global Head & Neck Cancer Therapeutics Market | Top Trends

  • Immunotherapy has demonstrated encouraging outcomes in the treatment of individuals with recurrent or metastatic head and neck cancer. Checkpoint inhibitors, such as pembrolizumab and nivolumab, have been licensed for the treatment of head and neck cancer and have shown better overall survival when compared to standard therapy. The field of immunotherapy is swiftly growing, with continuing research and multiple clinical studies aimed at improving treatment choices for head and neck cancer. To optimize outcomes, these studies investigate novel immunotherapeutic drugs, combination tactics, and treatment sequencing.
  • Radiotherapy advances like FLASH therapy and image-guided therapy are anticipated to drive the global head & neck cancer therapeutics market during the forecast period. Ultra-high dose rate (FLASH) radiation is a novel method of treating cancer-related tumors. Higher dosages of radiation are associated with trauma to the healthy tissue surrounding the tumor, whereas FLASH radiotherapy spares the healthy tissues while maintaining anti-tumor action.

MARKET SEGMENTATION

Market Segmentation – Therapeutic Class, Treatment Type, Route of Administration, and End-User

Market by Therapeutic Class: 

  • PD Inhibitors
    • PD inhibitors is set to be the dominating and fastest-growing therapeutic class during the forecast period.
    • PD inhibitors have increased survival rates and prolonged progression-free survival in patients with head and neck cancer, particularly those with advanced or recurrent illnesses. These encouraging results have increased demand for PD inhibitors as a preferred therapeutic choice, both as monotherapy and in combination with other medications.
    • The effectiveness of PD inhibitors in head and neck cancer has prompted a large number of clinical trials to assess their efficacy in a variety of contexts. These trials will seek to improve treatment techniques, uncover relevant biomarkers, and investigate novel combination tactics. For instance, in March 2023, the FDA approved Incyte’s PD-1 inhibitor called Zynyz.
  • EGFR Inhibitors
  • Microtubule Inhibitors

Market by Treatment Type:

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Surgery

Market by Route of Administration:

  • Injectable
  • Oral

Market by End-User: 

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
    • Ambulatory surgical centers is set to grow with a CAGR of 8.61% during the forecast period of 2023 to 2032.
    • The head & neck cancer therapeutics market is significantly fueled by the demand for ambulatory surgery centers (ASCs). For outpatient surgical treatments, ASCs provide a practical and affordable alternative to traditional hospital settings. ASCs also offer a good setting for carrying out these operations in some head and neck cancer cases where surgery is a primary or supplementary therapeutic option.
    • Increased disease prevalence and demand for affordable and quick treatment are driving the demand for ambulatory surgical centers. Technological advancements, greater surgical techniques, and regulatory revisions have facilitated the relocation of difficult surgical procedures to the ASC.
    • According to Axtria, almost 6,000 Medicare-certified ASCs treated three million enrollees in 2020. According to industry-wide research, ASCs continue to perform more than half of all outpatient surgical operations in the United States.
  • Other End-Users

 

GEOGRAPHICAL STUDY

GEOGRAPHICAL STUDY BASED ON FOUR MAJOR REGIONS:
  • North America: The United States and Canada
  • Europe: The United Kingdom, France, Germany, Spain, Italy, Poland, Nordic Countries, and Rest of Europe
  • Asia-Pacific: China, Japan, India, South Korea, Indonesia, Vietnam, Thailand, Australia & New Zealand, and Rest of Asia-Pacific
    • The Asia-Pacific head & neck cancer therapeutics market is set to grow with the highest CAGR during the forecast period. 
    • According to Novotech CRO, every year, around 4,000 Australians are diagnosed with head and neck cancer (HNC). This includes around 1,400 persons with mouth and tongue cancer, 935 with lip cancer, 1,000 with pharyngeal cancer, 600 with laryngeal cancer, 300 with salivary gland cancer, and 200 with nasal or paranasal sinus cancer. Males are approximately three times more likely than females to acquire head and neck cancer. The high patient pool in Australia is anticipated to drive the demand for head and neck cancer therapeutics during the forecast period.
    • Similarly, India experiences a high patient pool for head and neck cancers; the nation contributes 58% of all head and neck cancer patients worldwide. As a result of growing tobacco usage over the years, India currently accounts for roughly 60% of all head and neck cancer patients globally. Moreover, according to Globocan 2020, 135,929 new instances of oral and lip cancer were expected to be diagnosed in India in 2020.
  • Rest of World: Latin America, the Middle East & Africa

MAJOR PLAYERS

MAJOR PLAYERS IN THE GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET:

  • Amgen Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Sanofi
  • Sun Pharmaceutical Industries Ltd

Key strategies adopted by some of these companies:

  • In August 2022, Bristol-Myers Squibb Company completed the acquisition of Turning Point Therapeutics. This acquisition has offered Bristol-Myers Squibb a pipeline of investigational drugs, including repotrectinib.
  • PDS Biotechnology Corporation, in May 2021, established a collaboration with the Head and Neck Cancer Alliance to advance the knowledge of developing therapeutics for HPV-related head and neck cancer.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2023-2032
Base Year2022
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Segments AnalyzedTherapeutic Class, Treatment Type, Route of Administration, and End-User
Geographies AnalyzedNorth America, Europe, Asia-Pacific, and Rest of World
Companies AnalyzedAmgen Inc, AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd (Genetech Inc), Merck & Co Inc, Sun Pharmaceutical Industries Ltd, Pfizer

TABLE OF CONTENT

  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. CRISIS SCENARIO ANALYSIS
      1. IMPACT OF COVID-19 ON HEAD & NECK CANCER THERAPEUTICS MARKET
    5. MAJOR MARKET FINDINGS
      1. BIOMARKER-DRIVEN TREATMENTS OFFER ENHANCED EFFICIENCY
      2. MARKET EXPANSION IN EMERGING ECONOMIES
      3. COMBINATION THERAPY IMPROVES PATIENT SURVIVAL RATES
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. HIGH INCIDENCE OF HEAD & NECK CANCERS
      2. ADVANCEMENTS IN TREATMENT MODALITIES
      3. ADVANCES IN BIOCHEMISTRY AND GENOMICS
      4. INCREASING GERIATRIC POPULATION
    2. KEY RESTRAINTS
      1. SEVERE SIDE EFFECTS 
      2. HIGH TREATMENT COSTS
      3. LIMITED EFFECTIVE TREATMENT OPTIONS
  4. KEY ANALYTICS
    1. KEY TECHNOLOGY TRENDS
    2. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    3. GROWTH PROSPECT MAPPING
      1. GROWTH PROSPECT MAPPING FOR UNITED STATES
      2. GROWTH PROSPECT MAPPING FOR POLAND
      3. GROWTH PROSPECT MAPPING FOR INDIA
      4. GROWTH PROSPECT MAPPING FOR MIDDLE EAST & AFRICA
    4. MARKET MATURITY ANALYSIS
    5. MARKET CONCENTRATION ANALYSIS
    6. DIAGNOSTIC METHODS FOR HEAD & NECK CANCER
      1. BIOPSY
      2. IMAGING
      3. ENDOSCOPY
      4. OTHER METHODS
  5. MARKET BY THERAPEUTIC CLASS
    1. PD INHIBITORS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. EGFR INHIBITORS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. MICROTUBULE INHIBITORS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  6. MARKET BY TREATMENT TYPE
    1. CHEMOTHERAPY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. IMMUNOTHERAPY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. TARGETED THERAPY
      1. MARKET FORECAST THERAPY
      2. SEGMENT ANALYSIS
    4. RADIATION THERAPY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    5. SURGERY
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  7. MARKET BY ROUTE OF ADMINISTRATION
    1. INJECTABLE
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. ORAL
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  8. MARKET BY END-USER
    1. HOSPITALS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    2. SPECIALTY CLINICS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    3. AMBULATORY SURGICAL CENTERS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
    4. OTHER END-USERS
      1. MARKET FORECAST FIGURE
      2. SEGMENT ANALYSIS
  9. GEOGRAPHICAL ANALYSIS
    1. NORTH AMERICA
      1. MARKET SIZE & ESTIMATES
      2. NORTH AMERICA HEAD & NECK CANCER THERAPEUTICS MARKET DRIVERS
      3. NORTH AMERICA HEAD & NECK CANCER THERAPEUTICS MARKET CHALLENGES
      4. NORTH AMERICA HEAD & NECK CANCER THERAPEUTICS MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS OPERATING IN NORTH AMERICA HEAD & NECK CANCER THERAPEUTICS MARKET
      6. COUNTRY ANALYSIS
        1. UNITED STATES
          1. UNITED STATES HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        2. CANADA
          1. CANADA HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
    2. EUROPE
      1. MARKET SIZE & ESTIMATES
      2. EUROPE HEAD & NECK CANCER THERAPEUTICS MARKET DRIVERS
      3. EUROPE HEAD & NECK CANCER THERAPEUTICS MARKET CHALLENGES
      4. EUROPE HEAD & NECK CANCER THERAPEUTICS MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS OPERATING IN EUROPE HEAD & NECK CANCER THERAPEUTICS MARKET
      6. COUNTRY ANALYSIS
        1. UNITED KINGDOM
          1. UNITED KINGDOM HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        2. GERMANY
          1. GERMANY HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        3. FRANCE
          1. FRANCE HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        4. ITALY
          1. ITALY HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        5. SPAIN
          1. SPAIN HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        6. POLAND
          1. POLAND HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        7. NORDIC COUNTRIES
          1. NORDIC COUNTRIES HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        8. REST OF EUROPE
          1. REST OF EUROPE HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
    3. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. ASIA-PACIFIC HEAD & NECK CANCER THERAPEUTICS MARKET DRIVERS
      3. ASIA-PACIFIC HEAD & NECK CANCER THERAPEUTICS MARKET CHALLENGES
      4. ASIA-PACIFIC HEAD & NECK CANCER THERAPEUTICS MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS OPERATING IN ASIA-PACIFIC HEAD & NECK CANCER THERAPEUTICS MARKET
      6. COUNTRY ANALYSIS
        1. CHINA
          1. CHINA HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        2. JAPAN
          1. JAPAN HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        3. INDIA
          1. INDIA HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        4. SOUTH KOREA
          1. SOUTH KOREA HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        5. INDONESIA
          1. INDONESIA HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        6. THAILAND
          1. THAILAND HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        7. VIETNAM
          1. VIETNAM HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        8. AUSTRALIA & NEW ZEALAND
          1. AUSTRALIA & NEW ZEALAND HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        9. REST OF ASIA-PACIFIC
          1. REST OF ASIA-PACIFIC HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
    4. REST OF WORLD
      1. MARKET SIZE & ESTIMATES
      2. REST OF WORLD HEAD & NECK CANCER THERAPEUTICS MARKET DRIVERS
      3. REST OF WORLD HEAD & NECK CANCER THERAPEUTICS MARKET CHALLENGES
      4. REST OF WORLD HEAD & NECK CANCER THERAPEUTICS MARKET REGULATORY FRAMEWORK
      5. KEY PLAYERS OPERATING IN REST OF WORLD HEAD & NECK CANCER THERAPEUTICS MARKET
      6. REGIONAL ANALYSIS
        1. LATIN AMERICA
          1. LATIN AMERICA HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
        2. MIDDLE EAST & AFRICA
          1. MIDDLE EAST & AFRICA HEAD & NECK CANCER THERAPEUTICS MARKET SIZE & OPPORTUNITIES
  10. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
      4. BUSINESS EXPANSIONS & DIVESTITURES
    2. COMPANY PROFILES
      1. AMGEN INC
        1. COMPANY OVERVIEW
        2. PRODUCTS OVERVIEW
        3. STRENGTHS & CHALLENGES
      2. ASTRAZENECA PLC
        1. COMPANY OVERVIEW
        2. PRODUCTS OVERVIEW
        3. STRENGTHS & CHALLENGES
      3. BRISTOL-MYERS SQUIBB COMPANY
        1. COMPANY OVERVIEW
        2. PRODUCTS OVERVIEW
        3. STRENGTHS & CHALLENGES
      4. ELI LILLY AND COMPANY
        1. COMPANY OVERVIEW
        2. PRODUCTS OVERVIEW
        3. STRENGTHS & CHALLENGES
      5. F. HOFFMANN-LA ROCHE LTD (GENETECH INC)
        1. COMPANY OVERVIEW
        2. PRODUCTS OVERVIEW
        3. STRENGTHS & CHALLENGES
      6. MERCK & CO INC
        1. COMPANY OVERVIEW
        2. PRODUCTS OVERVIEW
        3. STRENGTHS & CHALLENGES
      7. NOVARTIS AG
        1. COMPANY OVERVIEW
        2. PRODUCTS OVERVIEW
        3. STRENGTHS & CHALLENGES
      8. PFIZER INC
        1. COMPANY OVERVIEW
        2. PRODUCTS OVERVIEW
        3. STRENGTHS & CHALLENGES
      9. SANOFI
        1. COMPANY OVERVIEW
        2. PRODUCTS OVERVIEW
        3. STRENGTHS & CHALLENGES
      10. SUN PHARMACEUTICAL INDUSTRIES LTD
        1. COMPANY OVERVIEW
        2. PRODUCTS OVERVIEW
        3. STRENGTHS & CHALLENGES

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – HEAD & NECK CANCER THERAPEUTICS

TABLE 2: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 3: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 4: GLOBAL PD INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 5: GLOBAL PD INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 6: GLOBAL EGFR INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 7: GLOBAL EGFR INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 8: GLOBAL MICROTUBULE INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 9: GLOBAL MICROTUBULE INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 10: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 11: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 12: GLOBAL CHEMOTHERAPY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 13: GLOBAL CHEMOTHERAPY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 14: GLOBAL IMMUNOTHERAPY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 15: GLOBAL IMMUNOTHERAPY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 16: GLOBAL TARGETED THERAPY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 17: GLOBAL TARGETED THERAPY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 18: GLOBAL RADIATION THERAPY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 19: GLOBAL RADIATION THERAPY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 20: GLOBAL SURGERY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 21: GLOBAL SURGERY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 22: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 23: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 24: GLOBAL INJECTABLE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 25: GLOBAL INJECTABLE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 26: GLOBAL ORAL MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 27: GLOBAL ORAL MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 28: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY END-USER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 29: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY END-USER, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 30: GLOBAL HOSPITALS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 31: GLOBAL HOSPITALS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 32: GLOBAL SPECIALTY CLINICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 33: GLOBAL SPECIALTY CLINICS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 34: GLOBAL AMBULATORY SURGICAL CENTERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 35: GLOBAL AMBULATORY SURGICAL CENTERS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 36: GLOBAL OTHER END-USERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 37: GLOBAL OTHER END-USERS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 38: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 39: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 40: NORTH AMERICA HEAD & NECK CANCER THERAPEUTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 41: NORTH AMERICA HEAD & NECK CANCER THERAPEUTICS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 42: NORTH AMERICA HEAD & NECK CANCER THERAPEUTICS MARKET REGULATORY FRAMEWORK

TABLE 43: KEY PLAYERS OPERATING IN NORTH AMERICA HEAD & NECK CANCER THERAPEUTICS MARKET

TABLE 44: EUROPE HEAD & NECK CANCER THERAPEUTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 45: EUROPE HEAD & NECK CANCER THERAPEUTICS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 46: EUROPE HEAD & NECK CANCER THERAPEUTICS MARKET REGULATORY FRAMEWORK

TABLE 47: KEY PLAYERS OPERATING IN EUROPE HEAD & NECK CANCER THERAPEUTICS MARKET

TABLE 48: ASIA-PACIFIC HEAD & NECK CANCER THERAPEUTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 49: ASIA-PACIFIC HEAD & NECK CANCER THERAPEUTICS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 50: ASIA-PACIFIC HEAD & NECK CANCER THERAPEUTICS MARKET REGULATORY FRAMEWORK

TABLE 51: KEY PLAYERS OPERATING IN ASIA-PACIFIC HEAD & NECK CANCER THERAPEUTICS MARKET

TABLE 52: REST OF WORLD HEAD & NECK CANCER THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 53: REST OF WORLD HEAD & NECK CANCER THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 54: REST OF WORLD HEAD & NECK CANCER THERAPEUTICS MARKET REGULATORY FRAMEWORK

TABLE 55: KEY PLAYERS OPERATING IN REST OF WORLD HEAD & NECK CANCER THERAPEUTICS MARKET

TABLE 56: LIST OF MERGERS & ACQUISITIONS

TABLE 57: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 58: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 59: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES 

FIGURE 1: KEY TECHNOLOGY TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING FOR UNITED STATES

FIGURE 4: GROWTH PROSPECT MAPPING FOR POLAND

FIGURE 5: GROWTH PROSPECT MAPPING FOR INDIA

FIGURE 6: GROWTH PROSPECT MAPPING FOR MIDDLE EAST & AFRICA

FIGURE 7: MARKET MATURITY ANALYSIS

FIGURE 8: MARKET CONCENTRATION ANALYSIS

FIGURE 9: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, GROWTH POTENTIAL, BY THERAPEUTIC CLASS, IN 2022

FIGURE 10: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY PD INHIBITORS, 2023-2032 (IN $ MILLION)

FIGURE 11: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY EGFR INHIBITORS, 2023-2032 (IN $ MILLION)

FIGURE 12: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY MICROTUBULE INHIBITORS, 2023-2032 (IN $ MILLION)

FIGURE 13: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, GROWTH POTENTIAL, BY TREATMENT TYPE, IN 2022

FIGURE 14: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY CHEMOTHERAPY, 2023-2032 (IN $ MILLION)

FIGURE 15: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY IMMUNOTHERAPY, 2023-2032 (IN $ MILLION)

FIGURE 16: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY TARGETED THERAPY, 2023-2032 (IN $ MILLION)

FIGURE 17: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY RADIATION THERAPY, 2023-2032 (IN $ MILLION)

FIGURE 18: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY SURGERY, 2023-2032 (IN $ MILLION)

FIGURE 19: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, GROWTH POTENTIAL, BY ROUTE OF ADMINISTRATION, IN 2022

FIGURE 20: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY INJECTABLE, 2023-2032 (IN $ MILLION)

FIGURE 21: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY ORAL, 2023-2032 (IN $ MILLION)

FIGURE 22: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, GROWTH POTENTIAL, BY END-USER, IN 2022

FIGURE 23: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY HOSPITALS, 2023-2032 (IN $ MILLION)

FIGURE 24: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY SPECIALTY CLINICS, 2023-2032 (IN $ MILLION)

FIGURE 25: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY AMBULATORY SURGICAL CENTERS, 2023-2032 (IN $ MILLION)

FIGURE 26: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY OTHER END-USERS, 2023-2032 (IN $ MILLION)

FIGURE 27: GLOBAL HEAD & NECK CANCER THERAPEUTICS MARKET, BY GEOGRAPHY, 2022 & 2032 (IN %)

FIGURE 28: NORTH AMERICA HEAD & NECK CANCER THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 29: UNITED STATES HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 30: CANADA HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION

FIGURE 31: EUROPE HEAD & NECK CANCER THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 32: UNITED KINGDOM HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 33: GERMANY HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 34: FRANCE HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 35: ITALY HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 36: SPAIN HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 37: POLAND HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 38: NORDIC COUNTRIES HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 39: REST OF EUROPE HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 40: ASIA-PACIFIC HEAD & NECK CANCER THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 41: CHINA HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 42: JAPAN HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 43: INDIA HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 44: SOUTH KOREA HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 45: INDONESIA HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 46: THAILAND HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 47: VIETNAM HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 48: AUSTRALIA & NEW ZEALAND HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 49: REST OF ASIA-PACIFIC HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 50: REST OF WORLD HEAD & NECK CANCER THERAPEUTICS MARKET, REGIONAL OUTLOOK, 2022 & 2032 (IN %)

FIGURE 51: LATIN AMERICA HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 52: MIDDLE EAST & AFRICA HEAD & NECK CANCER THERAPEUTICS MARKET, 2023-2032 (IN $ MILLION)

FAQ’s

FAQs

External beam radiation therapy is a treatment option for head and neck cancer. Moreover, intensity-modulated radiation therapy (IMRT) and proton therapy are cutting-edge procedures that enable precision tumor targeting while causing minimal damage to healthy tissues.

The stage of head and neck cancer is determined by the tumor’s size, dissemination to local lymph nodes, and metastasis to distant regions. Staging aids in determining the best treatment strategy and prognosis.